Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05298423
Title Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC

lung non-small cell carcinoma


Cisplatin + MK-7684A + Pemetrexed Disodium

Cisplatin + Durvalumab + Paclitaxel

Carboplatin + MK-7684A + Paclitaxel

Cisplatin + Etoposide + MK-7684A

Carboplatin + Durvalumab + Paclitaxel

Cisplatin + Durvalumab + Etoposide

Age Groups: adult | senior
Covered Countries USA | ESP | DEU

No variant requirements are available.